2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Infectious Diseases, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Pregnant, Young Adult
PAPER

2696 Corticosteroid use in patients with persistent or chronic primary immune thrombocytopenia (ITP) treated with advanced therapies in the United States

David J Kuter, MD, DPhil, Nancy El-Hoyek, PharmD, MSc2, David Farber, PharmD3, Maria Belen Rodriguez, MD4, Natalia Petruski-Ivleva, PhD5, Siddhi Umarje, PharmD, ScM6
1 Hematology Division, Massachusetts General Hospital, Boston, Massachusetts, United States
2 Sanofi, Cambridge, Massachusetts, United States
3 Sanofi, Cambridge, Massachusetts, United States
4 Sanofi, Cambridge, Massachusetts, United States
5 Sanofi, Cambridge, Massachusetts, United States
6 Sanofi, Morristown, New Jersey, United States

Introduction: Primary ITP is a rare autoimmune hematologic disorder of immune dysregulation characterized by increased platelet destruction, and impaired platelet production. Corticosteroids are commonly used as initial and rescue therapy. Use of advanced therapies is recommended among patients who respond inadequately to corticosteroids. This study quantified systemic (oral and intravenous [IV]) corticosteroid use, including dosing among persistent or chronic primary ITP patients receiving advanced therapies in the United States (US).

Methods: This retrospective comparative cohort study used administrative claims data from Optum’s de-identified Clinformatics® Data Mart Database. Adults (≥18 years) with persistent or chronic primary ITP (duration ≥3 months), initiating advanced therapies (thrombopoietin receptor agonists [TPO-RAs; eltrombopag, avatrombopag, and romiplostim], rituximab, or fostamatinib) between October 1, 2016, and April 4, 2022, indexed on date of advanced therapy initiation, were included. ITP patients were matched 1:5 to patients without ITP on age, sex, race/ethnicity, and year of cohort entry at the index date. Comorbidities and systemic corticosteroid use were assessed during the 365 days baseline period before index and systemic corticosteroid use was assessed in the 365 days follow-up after index. Oral corticosteroid use was described as proportion use, number of fills, days’ supply per fill, cumulative dose, and average daily dose. Difference in baseline comorbidities and corticosteroid use among ITP and patients without ITP were assessed using standardized mean difference (SMD; SMD >0.1 indicates statistically significant difference). Difference in corticosteroid use over 1-year follow-up was reported as difference in proportion with 95% confidence interval and p-value, measured using Chi-square test. Difference in mean and median cumulative corticosteroid dose was measured using 2-sample t-test.

Results: The analysis included 978 patients with persistent or chronic primary ITP matched to 4,785 patients without ITP. The mean (standard deviation [SD]) age of the study population was 65.6 (17.3) years, and the majority were White (70.3%). Patients with ITP had a higher burden of comorbidities than patients without ITP, including diabetes (30.1% vs 14.7%; SMD=0.4), hypertension (66.4% vs 50.1%; SMD=0.3), infections (13.8% vs 2.8%; SMD=0.4), overweight/obesity (25.9% vs 12.8%; SMD=0.3), and asthma (18.5% vs 11.1%; SMD=0.2). Among 978 patients, 61.8% received TPO-RAs (eltrombopag: 31.2%; avatrombopag: 1.5%; romiplostim: 29.1%), 37.3% received rituximab and 1.4% received fostamatinib. Baseline corticosteroids use 365 days prior to advanced therapy initiation was higher among patients with ITP than those without ITP (oral: 62.5% vs 12.6%, SMD=1.2; IV: 12.6% vs 4.8%, SMD=0.3) with a mean (SD) dose per fill of 867.2 (559.8) vs 208.3 (183.1) mg prednisone equivalent (PE); SMD=1.6 and mean (SD) of 2.2 (2.8) vs 0.2 (0.8) fills per year; SMD=1.0. The mean (SD) days’ supply per fill was 18.8 (15.2) vs 9.9 (13.1); SMD=0.6. The mean (SD) cumulative annual dose was significantly higher among patients with ITP than matched referents 2,841.6 (2,417.2) vs 430.3 (737.7) mg PE; SMD=1.4. Mean (SD) daily corticosteroid doses were 83.2 (81.2) and 27.3 (15.9) mg PE; SMD=1.0, respectively. Despite advanced therapy initiation, corticosteroid use over 1-year was significantly higher among ITP patients compared to those without ITP (oral: 40.6% vs 13.6%; IV: 11.6% vs 5.3%; p<0.001), with mean (SD) corticosteroid dose per fill of 629.5 (608.0) vs 223.3 (260.4) mg PE (p<0.001). Mean (SD) days’ supply per fill was 19.6 (17.8) vs 10.0 (13.4) days (p<0.001). The mean (SD) annual cumulative corticosteroid dose remained high at 1,791.3 (2,138.4) vs 473.9 (1,006.9) mg PE (p<0.001) with mean (SD) daily dose of 56.0 (76.2) vs 27.8 (18.7) mg PE (p<0.001).

Conclusions: Among patients with persistent or chronic primary ITP in the US receiving advanced therapies, a significant proportion still had corticosteroid use and dosing. Compared with matched controls, patients with ITP had significantly greater cumulative corticosteroid exposure before and after advanced therapy initiation. These findings highlight the need for treatment strategies that minimize corticosteroid use and cumulative exposure in clinical practice. Further research is warranted to evaluate the clinical consequences of prolonged corticosteroid use in this population.

David J Kuter, MD, DPhil: HUTCHMED - Research Funding; Sanofi - Research Funding; Fulcrum Therapeutics - Research Funding; Principia Biopharma - Research Funding; Novartis - Research Funding; Takeda - Research Funding; UCB - Consultancy (Includes expert testimony); Actelion - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Immunovant - Consultancy (Includes expert testimony); CVS Caremark - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Kyowa Kirin - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); BioCryst - Consultancy (Includes expert testimony); Principia Biopharma - Consultancy (Includes expert testimony); Daiichi Sankyo - Consultancy (Includes expert testimony); HUTCHMED - Consultancy (Includes expert testimony); UpToDate - Consultancy (Includes expert testimony); MSD - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Hengrui Pharmaceutical - Consultancy (Includes expert testimony); Genzyme - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Chugai Pharma - Consultancy (Includes expert testimony); Alpine Immune Sciences - Consultancy (Includes expert testimony); Verve - Consultancy (Includes expert testimony); Crico - Consultancy (Includes expert testimony); Platelet Disorder Support Association - Consultancy (Includes expert testimony); Alexion Pharmaceuticals - Consultancy (Includes expert testimony); Rigel - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)